Bayer’s (BAYN GY) Xofigo plus Enzalutamide demonstrates significant overall survival benefit in Peace-3 trial in patients with metastatic castration-resistant prostate cancer with bone metastases
Importance
Level 1
#GERMANY#EUROPE#BAYER AG#BAYN.GY#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BAYN#EURO STOXX 50#DAX 40 INDEX